Member Info for Sangijuelas1

Hopefully there might be some truth in some of that. It's just the gist of the article was that they were trying to tie hospitals up with equipment and a sticky process

The fact that they see it as an important target market is positive

Yeah but 4xben.I was looking at that the other day and they are very much a competitor to Point and they seem to be ahead although it's possible that Point have a superior offering.
I saw it as a potential threat to Point.

They would have known through their voting rights at the agm.

Conifer didn't do due diligence for a year to trade out for a small profit. It would go against their whole investment philosophy.

So an additional 2 sites with our old friend Dinesh Saralaya at Bradford as well

Very interesting, before they got the incredible data from 0518 the asthma candidate was the one generating the most excitement among the 4D scientists in terms of potential

No mention of exiting Avacta in this letter to Sequoia investors on 12 July

https://www.sequoiafund.com/Communications

I never bought the idea of them selling out. Their most recent investor update from a few months back mentioned trimming positions in the likes of Hiscox.

This was turned into a TRUTH by posters here who had it in their heads that Conifer were the only investor able to sell shares

Shame we don't have something like Oxford Nanopore whose IPO will include anti takeover shares held by the CEO who can veto any approaches because UK investors can't be trusted to sell out at the first sign of a payday

Yay takeover talk. Let's try and ramp things up to get back to 140 talking nonsense about takeovers.

Oooh £10bn what a lot of money. Let's sell Avacta for £10bn. What's that AS sees us as a challenger to Roche. What Roche what's worth £250bn?

Why are people incapable of just holding an investment? Oh I know it's because they are British cucks who think £10bn is a lot of money.

A happy holder and accumulator

Robins, Seres have a very different approach to 4D as they use consortia whereas we employ single strain.

Seres have screwed up so many times and given their recent deal with Nestle I wouldn't be surprised if they gave up on drugs and switched to less heavily regulated supplements.

Hope you aren't trying to talk it down for an entry point. Think I might give FNCH a go as they are well down as well

There are aready peeps posting on the Seres stocktwits about LBPS

Seres are a joke
Messed up another trial a few years ago which impacted the whole microbiome market
Then when they ran a P3 they did not include enough patients to meet the FDA requirements
Had to ditch their oncology trial and now this.

This article interesting given that Seres also messed up the drug trials for the one mentioned in the article
https://www.fiercebiotech.com/biotech/astrazeneca-taps-microbiome-specialist-seres-for-i-o-support

The article is relevant because it is another example of big pharma gaining confidence in the potential of the microbiome.

Potential collaboration or they might just stick a bid in

https://mobile.twitter.com/4dpharmaplc/status/1417524640298192899

Rorkes- ses the answer to the question in the investor presentation

Q26: Can you explain how a ‘professional use’ test is administered in the real world?

A professional use test can be carried out by a healthcare professional or trained individual. Therefore, in addition to healthcare or social care settings, a trained individual in a workplace, institution, organisation or any location can carry out or oversee the carrying out of a professional use test by a non-professional.

The common list is mainly for recognition between EU countries for things like the digital travel certificates. It is not a requirement for use within countries by businesses or other institutions.

It is getting updated more regularly now so could still make it on there.

And it was Martnotsmart who spotted it

Who cares if it's shorted? All stocks are. And it's summer which is when shorts always do best.

I say burn em

At least I do my uber ramping when the price is at rock bottom